
08 Aug EG427
Don Haut, Ph.D., Chief Business Officer
Oct. 9 | 11:00am | FLW Ballroom F
Paris, France
(Private)
EG 427 develops a unique vector platform to deliver pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Our vectors can achieve focal transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows either for long-term gene therapy, or all-in-one gene editing approaches. EG 427 is the second company to bring a non-replicating HSV-1 vector into clinical development with an IND filed with the FDA in May 2024. Our first product, EG110A, addresses multiple severe bladder diseases (including Neurogenic Bladder and Overactive Bladder) by targeting selectively sensory neurons and has the potential to be a major improvement over existing therapies, resulting in better care for the patients and lower costs for the healthcare systems.